Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes. (PubMed, Nat Commun) - Sep 24, 2026 - "The absolute difference in stroke risk was 2.1 percentage points at one year, and the absolute difference in mortality was 6.2 percentage points. These observational findings support further assessment of tirzepatide as a potential option for people with both conditions, but randomized trials are required before treatment recommendations can change."
Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Diabetes • Hematological Disorders • Ischemic stroke • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
Chia-Lun Chang; Chih-Lang Lin; Chih-Yuan Fang; Jung-Min Yu; Kuan-Chou Lin; Szu-Yuan Wu; Wan-Ming Chen; Yu-Yi Lin
|